Antibody Discovery Services Market - Global Forecast to 2030
商品番号 : SMB-86273
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年9月 |
| ページ数 | 380 |
| 図表数 | 470 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
本調査レポートでは、抗体探索サービス市場をタイプ別（ターゲット同定・検証、抗体エンジニアリング・最適化（ファージ／酵母ディスプレイ技術、ハイブリドーマ技術、単細胞技術、その他技術）、抗原設計・生産、免疫化・宿主管理、その他サービス）、宿主別（マウス・ラット、ウサギ、ニワトリ、ラクダ科動物、その他宿主）、分子別（モノクローナル抗体、ポリクローナル抗体、その他分子）、エンドユーザー別（製薬・バイオテクノロジー企業、学術研究機関、その他エンドユーザー）、地域別（北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東、アフリカ）に分類しています。レポートの範囲には、抗体探索サービス市場の成長に影響を与える推進要因、課題、機会、制約など、主要な要因に関する詳細な情報が網羅されています。主要業界プレーヤーの詳細な分析により、事業概要、サービスポートフォリオ、主要戦略（コラボレーション、パートナーシップ、事業拡大、契約、買収など）、そして抗体探索サービス市場に関連する最近の動向に関する洞察が得られました。本レポートは、抗体探索サービス市場エコシステムにおける主要プレーヤーと新興企業の競合分析を網羅しています。
本レポートは、抗体探索サービス市場の成長に影響を与える主要な要因（推進要因、制約要因、課題、機会など）に関する詳細な情報を網羅しています。主要業界プレーヤーを徹底的に分析し、事業概要、ソリューション、サービス、主要戦略、新製品・新サービスの発売、買収、抗体探索サービス市場に関連する最近の動向に関する洞察を提供しています。本レポートは、抗体探索サービス市場エコシステムにおける新興企業の競合分析を網羅しています。
本レポートは、抗体探索サービス市場の詳細な概要を提供します。タイプ、ホスト、分子、エンドユーザー、地域といった様々なセグメントにおける市場規模と将来の成長ポテンシャルを予測することを目的としています。また、主要市場プレーヤーの詳細な競合分析に加え、企業概要、最近の動向、主要な市場戦略も掲載しています。
抗体探索サービス市場は、2024年の19億米ドルから2030年には35億4000万米ドルに達し、予測期間中は年平均成長率（CAGR）13.3%で成長すると予測されています。抗体探索サービス市場の成長を牽引する要因としては、二重特異性抗体（bsAbs）やADCといった先進的なフォーマットの開発、ベンチャーキャピタルからの資金調達や戦略的パートナーシップの増加などが挙げられます。さらに、AIの統合とエンドツーエンドのサービスモデルの導入により、ワークフローの合理化、効率性の向上、そしてこの分野におけるイノベーションの加速が促進されています。
The antibody discovery services market is expected to reach 3.54 billion in 2030 from USD 1.90 billion in 2024, at a CAGR of 13.3% during the forecast period. Factors propelling the antibody discovery services market include the development of advanced formats such as bispecific antibodies (bsAbs) and ADCs, alongside rising venture funding and strategic partnerships. Moreover, the integration of AI and adoption of end-to-end service models are streamlining workflows, enhancing efficiency, and accelerating innovation in the field.
The mice & rats segment accounted for the largest share of the antibody discovery immunization & host management services market in 2024.
The market is segmented into mice & rats, rabbits, chickens, camelids, and other hosts. In 2024, the mouse & rat segment accounted for the largest share of the antibody discovery immunization & host management services market. These species remain the preferred choice due to their genetic similarity to humans, cost-effectiveness, and highly optimized breeding and experimental protocols. Their widespread use reflects well-established immunization workflows and robust host management infrastructure in preclinical antibody discovery efforts. Furthermore, the prevalence of mouse and rat models supports scalable, reproducible immunization services, facilitating rapid antibody generation through tried-and-tested immunological methods. This segmentation also enables service providers to tailor immunization strategies and host handling practices to well-characterized animal systems, enhancing predictability and efficiency. Collectively, these advantages cement the mouse & rat host segment as the dominant segment in immunization and host management services within the antibody discovery services market.
In 2024, by end user, the pharmaceutical & biotechnology companies segment accounted for the largest share of the market.
The antibody discovery services market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. In 2024, the pharmaceutical & biotechnology companies segment accounted for the largest share of the antibody discovery services market, driven by the scale of research and development activities directed toward therapeutic antibody programs. These companies manage extensive pipelines that require continuous discovery of new antibody candidates across oncology, immunology, infectious diseases, and other therapeutic areas. They invest heavily in advanced technologies such as phage display, hybridoma, and AI-based screening platforms provided by specialized service providers to support this. The high demand for outsourcing also reflects the need to streamline timelines, reduce internal costs, and access capabilities unavailable in-house. In addition, pharmaceutical and biotechnology firms pursue partnerships and collaborations that expand access to discovery platforms, enabling them to move efficiently from target identification to preclinical evaluation. The combination of broad therapeutic focus, large-scale investments, and reliance on external expertise established these companies as the leading contributors to market demand in 2024.
In 2024, North America accounted for the largest share of the antibody discovery services market.
North America accounted for the largest share of the antibody discovery services market in 2024. The region accounted for this position due to its concentration of pharmaceutical and biotechnology companies, research institutes, and contract service providers engaged in antibody development. Extensive funding for biomedical research from government agencies and private investors created a steady demand for discovery services. North America also benefits from a mature regulatory framework that supports the advancement of antibody-based therapeutics, enabling efficient progression from discovery to clinical evaluation. The presence of advanced research infrastructure, a skilled workforce, and established technology platforms further strengthened the region’s capacity to utilize and expand antibody discovery services. In addition, high clinical trial activity and strong collaborations between industry and academia contributed to sustained demand. Collectively, these factors positioned North America as the leading region in the global antibody discovery services market in 2024.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
- By Designation: C-level Executives – 55%, Directors- 20%, and Others- 25%
- By Region: North America -45%, Europe – 20%, Asia Pacific -20%, Latin America -10%, the Middle East- 3%, and Africa-2%
Charles River Laboratories (US), Thermo Fisher Scientific Inc. (US), WuXi Biologics (China), Aurigene Pharmaceutical Services Ltd. (India), EVOTEC (Germany), Sino Biological, Inc. (China), Shanghai ChemPartner (China), Biocytogen (China), Samsung Biologics (South Korea), Fusion Antibodies (UK), Twist Bioscience (US), Curia Global, Inc. (US), Danaher Corporation (US), Eurofins Scientific (Luxembourg), GenScript (US), Creative Biolabs (US), Viva Biotech (China), Harbour BioMed (China), ImmunoPrecise Antibodies Ltd. (Canada), Aragen Life Sciences Ltd. (India) are some of the key companies offering Antibody Discovery Services products.
Research Coverage
This research report categorizes the Antibody Discovery Services market by Type [Target Identification & Validation, Antibody Engineering & Optimization (Phage/Yeast Display Technology, Hybridoma Technology, Single-Cell Technologies, Other Technologies), Antigen Design & Production, Immunization & Host Management, Other Services], Immunization & Host Management By Host (Mice & Rats, Rabbits, Chickens, Camelids, Other Hosts), Molecule (Monoclonal Antibodies, Polyclonal Antibodies, Other Molecules), End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Other End Users), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the Antibody Discovery Services market. A detailed analysis of the key industry players has provided insights into their business overview, service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, acquisitions, and recent developments associated with the antibody discovery services market. This report covers a competitive analysis of top players and upcoming startups in the Antibody Discovery Services market ecosystem.
The scope of the report covers detailed information regarding the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the Antibody Discovery Services market. A thorough analysis of the key industry players has been conducted to provide insights into their business overview, solutions, and services; key strategies; new product & service launches, acquisitions, and recent developments associated with the Antibody Discovery Services market. This report covers the competitive analysis of upcoming startups in the Antibody Discovery Services market ecosystem.
Key Benefits of Buying the Report
This report provides a detailed picture of the antibody discovery services market. It aims to estimate the size and future growth potential of the market across different segments such as the type, host, molecule, end user, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles, recent developments, and key market strategies.
The report provides insights into the following pointers:
Analysis of key drivers (Development of new antibody formats, growing number of ADCs in clinical trials, rising funds for venture and partnership for biologics), restraints (High cost & complexity of biologics discovery, competition from alternative modalities, patent cliffs and rise of biosimilars), opportunities (end-to-end discovery-to-IND service bundles, integration of AI and automation in discovery workflow), Challenges (reagent & raw material supply chain bottlenecks, fragmented data and workflow infrastructure)
- Service Development/Innovation: Detailed insights on newly launched Services, and technological assessment of the antibody discovery services market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the antibody discovery services market across varied regions.
- Market Diversification: Exhaustive information about new, untapped geographies, recent developments, and investments in the antibody discovery services market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Charles River Laboratories (US), Thermo Fisher Scientific Inc. (US), WuXi Biologics (China), Aurigene Pharmaceutical Services Ltd. (India), EVOTEC (Germany), among others in the antibody discovery services market.
Table of Contents
1 INTRODUCTION 35
1.1 STUDY OBJECTIVES 35
1.2 MARKET DEFINITION 35
1.3 STUDY SCOPE 36
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 36
1.3.2 INCLUSIONS & EXCLUSIONS 37
1.4 YEARS CONSIDERED 37
1.4.1 CURRENCY CONSIDERED 38
1.5 STAKEHOLDERS 38
2 RESEARCH METHODOLOGY 39
2.1 RESEARCH DATA 39
2.1.1 SECONDARY DATA 40
2.1.1.1 Key secondary data sources 40
2.1.1.2 Key objectives of secondary research 40
2.1.2 PRIMARY DATA 41
2.1.2.1 Breakdown of primaries 41
2.1.2.2 Key objectives of primary research 42
2.2 MARKET ESTIMATION METHODOLOGY 42
2.2.1 MARKET ESTIMATION 43
2.2.1.1 Company revenue analysis (bottom-up approach) 43
2.2.1.2 MnM repository analysis & primary interviews 44
2.2.1.3 Insights from primary experts 45
2.2.1.4 Segmental market size estimation by top-down approach 45
2.3 MARKET GROWTH RATE PROJECTIONS 46
2.4 DATA TRIANGULATION 49
2.5 STUDY ASSUMPTIONS 50
2.6 RESEARCH LIMITATIONS 50
2.7 RISK ANALYSIS 51
3 EXECUTIVE SUMMARY 52
3.1 KEY INSIGHTS & MARKET HIGHLIGHTS 52
3.2 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS 57
3.3 DISRUPTIVE TRENDS SHAPING ANTIBODY DISCOVERY SERVICES MARKET 57
3.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 58
3.5 GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 60
4 PREMIUM INSIGHTS 61
4.1 ANTIBODY DISCOVERY SERVICES MARKET OVERVIEW 61
4.2 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE AND COUNTRY (2024) 62
4.3 ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2025 VS. 2030 63
4.4 ANTIBODY DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 63
4.5 ANTIBODY DISCOVERY SERVICES MARKET SHARE, BY TYPE 64
4.6 UNMET NEEDS & WHITE SPACES 64
4.7 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 65
4.8 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS 66
4.9 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 67
4.10 VC/PRIVATE EQUITY INVESTMENT TRENDS 68
4.11 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 69
4.11.1 SUSTAINABILITY IMPACT 69
4.11.2 REGULATORY POLICIES & ACCESS INITIATIVES 69
4.12 IP/PATENT LANDSCAPE IN ANTIBODY DISCOVERY SERVICES MARKET 69
5 MARKET OVERVIEW 71
5.1 INTRODUCTION 71
5.2 MARKET DYNAMICS 71
5.2.1 DRIVERS 72
5.2.1.1 Development of bispecific antibodies and antibody fragments 72
5.2.1.2 Rising number of antibody-drug conjugates in clinical trials 73
5.2.1.3 Increasing venture and partnership funding for biologics 73
5.2.2 RESTRAINTS 74
5.2.2.1 High costs and complexity of biologics discovery 74
5.2.2.2 Competition from alternative modalities 74
5.2.2.3 Patent cliffs for blockbuster monoclonal antibodies and
rise of biosimilars 74
5.2.3 OPPORTUNITIES 75
5.2.3.1 End-to-end discovery–to–IND service bundles/one-stop shop models in antibody discovery 75
5.2.3.2 Integration of AI and automation in discovery workflow 75
5.2.4 CHALLENGES 76
5.2.4.1 Reagents and raw material supply chain bottlenecks 76
5.2.4.2 Fragmented data and disjointed workflow infrastructure 76
6 INDUSTRY TRENDS 77
6.1 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 77
6.2 VALUE CHAIN ANALYSIS 78
6.3 ECOSYSTEM ANALYSIS 79
6.3.1 RAW MATERIAL SUPPLIERS 79
6.3.2 ANTIBODY DISCOVERY SERVICE PROVIDERS 80
6.3.3 END USERS 80
6.3.4 REGULATORY BODIES 81
6.4 INVESTMENT & FUNDING SCENARIO 82
6.4.1 MAJOR INVESTMENTS AND FUNDING 82
6.5 TECHNOLOGY ANALYSIS 83
6.5.1 KEY TECHNOLOGIES 83
6.5.1.1 Phage display platforms 83
6.5.1.2 Hybridoma technology 83
6.5.1.3 Single B-cell screening 84
6.5.2 COMPLEMENTARY TECHNOLOGIES 84
6.5.2.1 AI/ML-based protein structure prediction 84
6.5.2.2 Surface plasmon resonance (SPR)/Bio-layer interferometry (BLI) 84
6.5.2.3 Cryo-electron microscopy (CRYO-EM) 85
6.5.3 ADJACENT TECHNOLOGIES 85
6.5.3.1 CRISPR-based functional genomics 85
6.5.3.2 CHO cell line development 85
6.5.3.3 In-vivo modelling 86
6.6 PATENT ANALYSIS 86
6.6.1 METHODOLOGY 86
6.6.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014−2024 86
6.6.3 LIST OF KEY PATENTS 88
6.7 KEY CONFERENCES & EVENTS, 2025–2026 89
6.8 CASE STUDY ANALYSIS 90
6.8.1 BISPECIFIC ANTIBODY MANUFACTURABILITY ASSESSMENT AND OPTIMIZATION 90
6.8.2 ACCELERATING ANTIBODY DISCOVERY FOR PANDEMIC PREPAREDNESS 90
6.8.3 USE OF REPAB POLYCLONAL ANTIBODY SEQUENCING PLATFORM TO TO IDENTIFY PROTECTIVE ANTIBODIES FROM HUMAN HOSTS IMMUNE TO MALARIA 90
6.9 REGULATORY ANALYSIS 91
6.9.1 REGULATORY LANDSCAPE 91
6.9.1.1 North America 91
6.9.1.2 Europe 91
6.9.1.3 Asia Pacific 91
6.9.1.4 Rest of the World 91
6.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
6.10 PORTER’S FIVE FORCES ANALYSIS 94
6.10.1 BARGAINING POWER OF SUPPLIERS 95
6.10.2 BARGAINING POWER OF BUYERS 95
6.10.3 THREAT OF NEW ENTRANTS 96
6.10.4 THREAT OF SUBSTITUTES 96
6.10.5 INTENSITY OF COMPETITIVE RIVALRY 96
6.11 KEY STAKEHOLDERS & BUYING CRITERIA 97
6.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 97
6.11.2 KEY BUYING CRITERIA 98
6.12 IMPACT OF AI/GEN AI ON ANTIBODY DISCOVERY SERVICES MARKET 99
6.12.1 INTRODUCTION 99
6.12.2 MARKET POTENTIAL OF AI 99
7 ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE 101
7.1 INTRODUCTION 102
7.2 TARGET IDENTIFICATION & VALIDATION 102
7.2.1 INTEGRATION OF OMICS-DRIVEN INSIGHTS WITH HIGH-THROUGHPUT FUNCTIONAL VALIDATION TO PROPEL MARKET GROWTH 102
7.3 ANTIBODY ENGINEERING & OPTIMIZATION 106
7.3.1 ANTIBODY ENGINEERING & OPTIMIZATION, BY TECHNOLOGY 110
7.3.1.1 Phage display technology 110
7.3.1.1.1 Adoption of AI-enhanced phage display to augment segment growth 110
7.3.1.2 Hybridoma technology 114
7.3.1.2.1 Advancements in automation and single-cell integration to support segment growth 114
7.3.1.3 Single-cell technologies 117
7.3.1.3.1 Use of high-throughput, single-cell platforms to boost segment growth 117
7.3.1.4 Other antibody engineering & optimization technologies 121
7.4 ANTIGEN DESIGN & PRODUCTION 125
7.4.1 HIGH-QUALITY ANTIGEN DESIGN AND PRODUCTION TO SPUR SEGMENT GROWTH 125
7.5 IMMUNIZATION & HOST MANAGEMENT 129
7.5.1 RISING ADOPTION OF ADVANCED TRANSGENIC AND HUMANIZED MODELS TO PROPEL SEGMENT GROWTH 129
7.6 OTHER ANTIBODY DISCOVERY SERVICES 132
8 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST 136
8.1 INTRODUCTION 137
8.2 MOUSE & RAT 137
8.2.1 GROWING PRECLINICAL RESEARCH DEMAND TO DRIVE GROWTH 137
8.3 RABBIT 141
8.3.1 INCREASED RESEARCH AND DIAGNOSTIC APPLICATIONS TO FAVOR MARKET GROWTH 141
8.4 CHICKEN 144
8.4.1 INCREASING FOCUS OF THERAPEUTIC AND DIAGNOSTIC APPLICATIONS TO DRIVE MARKET 144
8.5 CAMELIDS 148
8.5.1 RISING ADOPTION OF NANOBODIES IN THERAPEUTICS AND DIAGNOSTICS TO BOOST MARKET GROWTH 148
8.6 OTHER HOSTS 151
9 ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE 155
9.1 INTRODUCTION 156
9.2 MONOCLONAL ANTIBODIES 156
9.2.1 GROWING ADOPTION IN TISSUE TYPING FOR ORGAN & BLOOD TRANSPLANTS AND PERSONALIZED MEDICINES TO DRIVE MARKET 156
9.3 POLYCLONAL ANTIBODIES 160
9.3.1 DIVERSE EPITOPE RECOGNITION ABILITY OF POLYCLONAL ANTIBODIES TO SUPPORT SEGMENT GROWTH 160
9.4 OTHER MOLECULES 163
10 ANTIBODY DISCOVERY SERVICES MARKET, BY END USER 167
10.1 INTRODUCTION 168
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 168
10.2.1 STRATEGIC COLLABORATIONS AND AI INTEGRATION TO BOLSTER GROWTH 168
10.3 ACADEMIC & RESEARCH INSTITUTES 172
10.3.1 INCREASING COLLABORATIVE RESEARCH AND RISING GRANT FUNDING TO AUGMENT MARKET GROWTH 172
10.4 OTHER END USERS 175
11 ANTIBODY DISCOVERY SERVICES MARKET, BY REGION 179
11.1 INTRODUCTION 180
11.2 NORTH AMERICA 181
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 184
11.2.2 US 185
11.2.2.1 US to dominate antibody discovery services market during forecast period 185
11.2.3 CANADA 188
11.2.3.1 Innovative biotech community and strategic platform investments to propel market growth 188
11.3 EUROPE 191
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 194
11.3.2 GERMANY 195
11.3.2.1 Transformative cross-border acquisitions and platform-driven antibody innovation to expedite market growth 195
11.3.3 UK 198
11.3.3.1 Ramped ADC innovation and surging biotech investment to propel market growth 198
11.3.4 FRANCE 201
11.3.4.1 Strategic biomanufacturing investments and AI-enabled innovation to support market expansion 201
11.3.5 ITALY 204
11.3.5.1 Advanced R&D infrastructure and biotech innovation to aid market growth 204
11.3.6 SPAIN 207
11.3.6.1 High biotech investment and innovation in advanced antibody modalities to drive market 207
11.3.7 REST OF EUROPE 210
11.4 ASIA PACIFIC 213
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 216
11.4.2 CHINA 217
11.4.2.1 Scalable integrated platforms, strategic global certification, and domestic innovation acceleration to augment market growth 217
11.4.3 JAPAN 220
11.4.3.1 Enhanced translational platforms and strategic cross-border R&D partnerships to expedite market growth 220
11.4.4 INDIA 223
11.4.4.1 Advanced biomanufacturing platforms and innovation-led public-private partnerships to strengthen Indian market 223
11.4.5 SOUTH KOREA 226
11.4.5.1 AI platform investments and CDMO-led modality innovation to accelerate market growth 226
11.4.6 AUSTRALIA 229
11.4.6.1 High-throughput single-cell platforms and increased academic-industry collaborations to spur market growth 229
11.4.7 REST OF ASIA PACIFIC 232
11.5 LATIN AMERICA 235
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 238
11.5.2 BRAZIL 239
11.5.2.1 Local biologics infrastructure expansion and collaborative innovation ecosystems to favor market growth 239
11.5.3 MEXICO 241
11.5.3.1 Focus on local emerging startups and industry-academic collaborations to aid antibody discovery services 241
11.5.4 REST OF LATIN AMERICA 244
11.6 MIDDLE EAST 247
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 250
11.6.2 GCC COUNTRIES 251
11.6.2.1 UAE 253
11.6.2.1.1 High biomanufacturing investments and focus on global pharmaceutical partnerships to fuel market growth 253
11.6.2.2 Kingdom of Saudi Arabia 256
11.6.2.2.1 Advanced biologics infrastructure and strategic life science innovation hubs to bolster market growth 256
11.6.2.3 Rest of GCC Countries 259
11.6.3 REST OF MIDDLE EAST 262
11.7 AFRICA 265
11.7.1 ADVANCED REGIONAL MANUFACTURING CAPABILITIES AND BIOTECH INNOVATION ECOSYSTEMS TO DRIVE MARKET 265
11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 268
12 COMPETITIVE LANDSCAPE 269
12.1 INTRODUCTION 269
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 269
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ANTIBODY DISCOVERY SERVICES MARKET 269
12.3 REVENUE ANALYSIS, 2020–2024 271
12.4 MARKET SHARE ANALYSIS, 2024 273
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 275
12.5.1 STARS 275
12.5.2 EMERGING LEADERS 275
12.5.3 PERVASIVE PLAYERS 275
12.5.4 PARTICIPANTS 275
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 277
12.5.5.1 Company footprint 277
12.5.5.2 Region footprint 278
12.5.5.3 Type footprint 279
12.5.5.4 Host footprint 280
12.5.5.5 Molecule footprint 281
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 282
12.6.1 PROGRESSIVE COMPANIES 282
12.6.2 RESPONSIVE COMPANIES 282
12.6.3 DYNAMIC COMPANIES 282
12.6.4 STARTING BLOCKS 282
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 284
12.6.5.1 List of key startups/SMEs 284
12.6.5.2 Competitive benchmarking of key startups/SMEs 285
12.7 COMPANY VALUATION & FINANCIAL METRICS 286
12.7.1 FINANCIAL METRICS 286
12.7.2 COMPANY VALUATION 286
12.8 BRAND/SERVICE COMPARISON 287
12.9 COMPETITIVE SCENARIO 288
12.9.1 SERVICE LAUNCHES 288
12.9.2 DEALS 288
12.9.3 EXPANSIONS 289
13 COMPANY PROFILES 291
13.1 KEY PLAYERS 291
13.1.1 WUXI BIOLOGICS 291
13.1.1.1 Business overview 291
13.1.1.2 Services offered 292
13.1.1.3 Recent developments 293
13.1.1.3.1 Deals 293
13.1.1.3.2 Expansions 294
13.1.1.4 MnM view 294
13.1.1.4.1 Right to win 294
13.1.1.4.2 Strategic choices 294
13.1.1.4.3 Weaknesses & competitive threats 294
13.1.2 THERMO FISHER SCIENTIFIC INC. 295
13.1.2.1 Business overview 295
13.1.2.2 Services offered 296
13.1.2.3 Recent developments 297
13.1.2.3.1 Deals 297
13.1.2.3.2 Expansions 298
13.1.2.4 MnM view 299
13.1.2.4.1 Right to win 299
13.1.2.4.2 Strategic choices 299
13.1.2.4.3 Weaknesses & competitive threats 299
13.1.3 CHARLES RIVER LABORATORIES 300
13.1.3.1 Business overview 300
13.1.3.2 Services offered 301
13.1.3.3 Recent developments 302
13.1.3.3.1 Deals 302
13.1.3.4 MnM view 303
13.1.3.4.1 Right to win 303
13.1.3.4.2 Strategic choices 303
13.1.3.4.3 Weaknesses & competitive threats 303
13.1.4 EVOTEC 304
13.1.4.1 Business overview 304
13.1.4.2 Services offered 305
13.1.4.3 Recent developments 306
13.1.4.3.1 Deals 306
13.1.4.3.2 Contracts 307
13.1.4.3.3 Expansions 307
13.1.4.3.4 Other developments 308
13.1.4.4 MnM view 308
13.1.4.4.1 Right to win 308
13.1.4.4.2 Strategic choices 308
13.1.4.4.3 Weaknesses & competitive threats 308
13.1.5 BIOCYTOGEN 309
13.1.5.1 Business overview 309
13.1.5.2 Services offered 310
13.1.5.3 Recent developments 311
13.1.5.3.1 Service launches 311
13.1.5.3.2 Deals 311
13.1.5.3.3 Expansions 313
13.1.5.4 MnM view 313
13.1.5.4.1 Right to win 313
13.1.5.4.2 Strategic choices 313
13.1.5.4.3 Weaknesses & competitive threats 314
13.1.6 EUROFINS SCIENTIFIC 315
13.1.6.1 Business overview 315
13.1.6.2 Services offered 316
13.1.6.3 Recent developments 317
13.1.6.3.1 Expansions 317
13.1.7 SHANGHAI CHEMPARTNER 318
13.1.7.1 Business overview 318
13.1.7.2 Services offered 318
13.1.7.3 Recent developments 319
13.1.7.3.1 Deals 319
13.1.8 AURIGENE PHARMACEUTICAL SERVICES LTD. (DR. REDDY’S LABORATORIES) 320
13.1.8.1 Business overview 320
13.1.8.2 Services offered 322
13.1.8.3 Recent developments 323
13.1.8.3.1 Expansions 323
13.1.9 SINO BIOLOGICAL, INC. 324
13.1.9.1 Business overview 324
13.1.9.2 Services offered 325
13.1.9.3 Recent developments 326
13.1.9.3.1 Deals 326
13.1.9.3.2 Expansions 327
13.1.10 SAMSUNG BIOLOGICS 328
13.1.10.1 Business overview 328
13.1.10.2 Services offered 329
13.1.10.3 Recent developments 330
13.1.10.3.1 Service launches 330
13.1.11 GENSCRIPT 331
13.1.11.1 Business overview 331
13.1.11.2 Services offered 332
13.1.11.3 Recent developments 333
13.1.11.3.1 Service launches 333
13.1.11.3.2 Deals 334
13.1.12 CURIA GLOBAL, INC. 335
13.1.12.1 Business overview 335
13.1.12.2 Services offered 335
13.1.12.3 Recent developments 336
13.1.12.3.1 Deals 336
13.1.12.3.2 Other developments 337
13.1.13 TWIST BIOSCIENCE 338
13.1.13.1 Business overview 338
13.1.13.2 Services offered 339
13.1.13.3 Recent developments 341
13.1.13.3.1 Service launches 341
13.1.13.3.2 Deals 341
13.1.13.3.3 Expansions 341
13.1.14 HARBOUR BIOMED 342
13.1.14.1 Business overview 342
13.1.14.2 Services offered 343
13.1.14.3 Recent developments 343
13.1.14.3.1 Deals 343
13.1.14.3.2 Other developments 345
13.1.15 ARAGEN LIFE SCIENCES LTD. 346
13.1.15.1 Business overview 346
13.1.15.2 Services offered 347
13.1.15.3 Recent developments 347
13.1.15.3.1 Expansions 347
13.1.16 DANAHER CORPORATION 348
13.1.16.1 Business overview 348
13.1.16.2 Services offered 349
13.1.16.3 Recent developments 350
13.1.16.3.1 Deals 350
13.1.17 CREATIVE BIOLABS 351
13.1.17.1 Business overview 351
13.1.17.2 Services offered 351
13.1.18 VIVA BIOTECH 353
13.1.18.1 Business overview 353
13.1.18.2 Services offered 355
13.1.19 IMMUNOPRECISE ANTIBODIES LTD. 356
13.1.19.1 Business overview 356
13.1.19.2 Services offered 357
13.1.19.3 Recent developments 359
13.1.19.3.1 Deals 359
13.1.20 FUSION ANTIBODIES 360
13.1.20.1 Business overview 360
13.1.20.2 Services offered 361
13.2 OTHER PLAYERS 363
13.2.1 ABZENA 363
13.2.2 ALLOY THERAPEUTICS, INC. 364
13.2.3 INTEGRAL MOLECULAR 365
13.2.4 BIODURO 366
13.2.5 SYNBIO TECHNOLOGIES 367
13.2.6 ABSOLUTE ANTIBODY 368
13.2.7 ADIMAB 369
13.2.8 ISOGENICA 370
13.2.9 ABLEXIS 371
13.2.10 FAIRJOURNEY 372
14 APPENDIX 373
14.1 DISCUSSION GUIDE 373
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 376
14.3 CUSTOMIZATION OPTIONS 378
14.4 RELATED REPORTS 378
14.5 AUTHOR DETAILS 379
LIST OF TABLES
TABLE 1 ANTIBODY DISCOVERY SERVICES MARKET: INCLUSIONS & EXCLUSIONS 37
TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS IN ANTIBODY DISCOVERY SERVICES MARKET 48
TABLE 3 ANTIBODY DISCOVERY SERVICES MARKET: RISK ANALYSIS 51
TABLE 4 KEY IP/PLATFORM ASSETS OF KEY PLAYERS, 2022–2025 70
TABLE 5 IMPACT ANALYSIS OF ANTIBODY DISCOVERY SERVICES MARKET DYNAMICS 72
TABLE 6 MAJOR VENTURE AND PARTNERSHIP FUNDING FOR BIOLOGICS, 2025 73
TABLE 7 ROLE OF RAW MATERIAL SUPPLIERS IN ANTIBODY DISCOVERY SERVICES MARKET ECOSYSTEM 80
TABLE 8 ROLE OF ANTIBODY DISCOVERY SERVICE PROVIDERS IN ANTIBODY DISCOVERY SERVICES MARKET ECOSYSTEM 80
TABLE 9 ROLE OF END USERS IN ANTIBODY DISCOVERY SERVICES MARKET ECOSYSTEM 81
TABLE 10 ROLE OF REGULATORY BODIES IN ANTIBODY DISCOVERY SERVICES MARKET ECOSYSTEM 81
TABLE 11 NUMBER OF PATENTS FILED (APPLIED/GRANTED) IN ANTIBODY DISCOVERY SERVICES MARKET, 2014−2024 86
TABLE 12 LIST OF KEY PATENTS IN ANTIBODY DISCOVERY SERVICES MARKET 88
TABLE 13 LIST OF KEY CONFERENCES & EVENTS IN ANTIBODY DISCOVERY SERVICES MARKET, JANUARY 2025–DECEMBER 2026 89
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
TABLE 17 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
TABLE 18 ANTIBODY DISCOVERY SERVICES MARKET: PORTER’S FIVE FORCES 94
TABLE 19 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%), BY TYPE 97
TABLE 20 KEY BUYING CRITERIA FOR MAJOR END USERS 98
TABLE 21 KEY PLAYERS IMPLEMENTING AI IN ANTIBODY DISCOVERY SERVICES 100
TABLE 22 ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 102
TABLE 23 TARGET IDENTIFICATION & VALIDATION MARKET, BY REGION,
2023–2030 (USD MILLION) 103
TABLE 24 NORTH AMERICA: TARGET IDENTIFICATION & VALIDATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 103
TABLE 25 EUROPE: TARGET IDENTIFICATION & VALIDATION MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 104
TABLE 26 ASIA PACIFIC: TARGET IDENTIFICATION & VALIDATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104
TABLE 27 LATIN AMERICA: TARGET IDENTIFICATION & VALIDATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 105
TABLE 28 MIDDLE EAST: TARGET IDENTIFICATION & VALIDATION MARKET, BY REGION, 2023–2030 (USD MILLION) 105
TABLE 29 GCC COUNTRIES: TARGET IDENTIFICATION & VALIDATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 105
TABLE 30 ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY REGION,
2023–2030 (USD MILLION) 106
TABLE 31 NORTH AMERICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 107
TABLE 32 EUROPE: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107
TABLE 33 ASIA PACIFIC: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 108
TABLE 34 LATIN AMERICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 108
TABLE 35 MIDDLE EAST: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY REGION, 2023–2030 (USD MILLION) 109
TABLE 36 GCC COUNTRIES: ANTIBODY ENGINEERING & OPTIMIZATION MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 109
TABLE 37 ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 110
TABLE 38 PHAGE DISPLAY TECHNOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION) 111
TABLE 39 NORTH AMERICA: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 111
TABLE 40 EUROPE: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 112
TABLE 41 ASIA PACIFIC: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 112
TABLE 42 LATIN AMERICA: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 113
TABLE 43 MIDDLE EAST: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 113
TABLE 44 GCC COUNTRIES: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 114
TABLE 45 HYBRIDOMA TECHNOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION) 114
TABLE 46 NORTH AMERICA: HYBRIDOMA TECHNOLOGY MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 115
TABLE 47 EUROPE: HYBRIDOMA TECHNOLOGY MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 115
TABLE 48 ASIA PACIFIC: HYBRIDOMA TECHNOLOGY MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 116
TABLE 49 LATIN AMERICA: HYBRIDOMA TECHNOLOGY MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 116
TABLE 50 MIDDLE EAST: HYBRIDOMA TECHNOLOGY MARKET, BY REGION,
2023–2030 (USD MILLION) 117
TABLE 51 GCC COUNTRIES: HYBRIDOMA TECHNOLOGY MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 117
TABLE 52 SINGLE-CELL TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 118
TABLE 53 NORTH AMERICA: SINGLE-CELL TECHNOLOGIES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 118
TABLE 54 EUROPE: SINGLE-CELL TECHNOLOGIES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 119
TABLE 55 ASIA PACIFIC: SINGLE-CELL TECHNOLOGIES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 119
TABLE 56 LATIN AMERICA: SINGLE-CELL TECHNOLOGIES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 120
TABLE 57 MIDDLE EAST: SINGLE-CELL TECHNOLOGIES MARKET, BY REGION,
2023–2030 (USD MILLION) 120
TABLE 58 GCC COUNTRIES: SINGLE-CELL TECHNOLOGIES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 121
TABLE 59 OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET,
BY REGION, 2023–2030 (USD MILLION) 122
TABLE 60 NORTH AMERICA: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122
TABLE 61 EUROPE: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 123
TABLE 62 ASIA PACIFIC: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 123
TABLE 63 LATIN AMERICA: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 124
TABLE 64 MIDDLE EAST: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 124
TABLE 65 GCC COUNTRIES: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 125
TABLE 66 ANTIGEN DESIGN & PRODUCTION MARKET, BY REGION,
2023–2030 (USD MILLION) 126
TABLE 67 NORTH AMERICA: ANTIGEN DESIGN & PRODUCTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 68 EUROPE: ANTIGEN DESIGN & PRODUCTION MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 127
TABLE 69 ASIA PACIFIC: ANTIGEN DESIGN & PRODUCTION MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 127
TABLE 70 LATIN AMERICA: ANTIGEN DESIGN & PRODUCTION MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 128
TABLE 71 MIDDLE EAST: ANTIGEN DESIGN & PRODUCTION MARKET, BY REGION,
2023–2030 (USD MILLION) 128
TABLE 72 GCC COUNTRIES: ANTIGEN DESIGN & PRODUCTION MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 128
TABLE 73 IMMUNIZATION & HOST MANAGEMENT MARKET, BY REGION,
2023–2030 (USD MILLION) 129
TABLE 74 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 130
TABLE 75 EUROPE: IMMUNIZATION & HOST MANAGEMENT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 130
TABLE 76 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 77 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 78 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT MARKET, BY REGION, 2023–2030 (USD MILLION) 132
TABLE 79 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 80 OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY REGION,
2023–2030 (USD MILLION) 133
TABLE 81 NORTH AMERICA: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 133
TABLE 82 EUROPE: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 134
TABLE 83 ASIA PACIFIC: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 84 LATIN AMERICA: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 85 MIDDLE EAST: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 135
TABLE 86 GCC COUNTRIES: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 87 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST,
2023–2030 (USD MILLION) 137
TABLE 88 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT,
BY REGION, 2023–2030 (USD MILLION) 138
TABLE 89 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 90 EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY COUNTRY, 2023–2030 (USD MILLION) 139
TABLE 91 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY COUNTRY, 2023–2030 (USD MILLION) 139
TABLE 92 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 93 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY REGION, 2023–2030 (USD MILLION) 140
TABLE 94 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 95 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT,
BY REGION, 2023–2030 (USD MILLION) 141
TABLE 96 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY COUNTRY, 2023–2030 (USD MILLION) 142
TABLE 97 EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY COUNTRY, 2023–2030 (USD MILLION) 142
TABLE 98 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY COUNTRY, 2023–2030 (USD MILLION) 143
TABLE 99 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY COUNTRY, 2023–2030 (USD MILLION) 143
TABLE 100 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY REGION, 2023–2030 (USD MILLION) 144
TABLE 101 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 102 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN,
BY REGION, 2023–2030 (USD MILLION) 145
TABLE 103 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY COUNTRY, 2023–2030 (USD MILLION) 145
TABLE 104 EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY COUNTRY, 2023–2030 (USD MILLION) 146
TABLE 105 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY COUNTRY, 2023–2030 (USD MILLION) 146
TABLE 106 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY COUNTRY, 2023–2030 (USD MILLION) 147
TABLE 107 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY REGION, 2023–2030 (USD MILLION) 147
TABLE 108 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY COUNTRY, 2023–2030 (USD MILLION) 147
TABLE 109 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS,
BY REGION, 2023–2030 (USD MILLION) 148
TABLE 110 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY COUNTRY, 2023–2030 (USD MILLION) 149
TABLE 111 EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY COUNTRY, 2023–2030 (USD MILLION) 149
TABLE 112 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 113 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 114 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY REGION, 2023–2030 (USD MILLION) 151
TABLE 115 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY COUNTRY, 2023–2030 (USD MILLION) 151
TABLE 116 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS,
BY REGION, 2023–2030 (USD MILLION) 152
TABLE 117 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY COUNTRY, 2023–2030 (USD MILLION) 152
TABLE 118 EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 119 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 120 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY COUNTRY, 2023–2030 (USD MILLION) 154
TABLE 121 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY REGION, 2023–2030 (USD MILLION) 154
TABLE 122 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY COUNTRY, 2023–2030 (USD MILLION) 154
TABLE 123 ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 156
TABLE 124 ANTIBODY DISCOVERY SERVICES MARKET FOR MONOCLONAL ANTIBODIES,
BY REGION, 2023–2030 (USD MILLION) 157
TABLE 125 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 157
TABLE 126 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 158
TABLE 127 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 158
TABLE 128 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 159
TABLE 129 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION) 159
TABLE 130 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 159
TABLE 131 ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES,
BY REGION, 2023–2030 (USD MILLION) 160
TABLE 132 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 161
TABLE 133 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 161
TABLE 134 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 162
TABLE 135 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 162
TABLE 136 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION) 163
TABLE 137 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 163
TABLE 138 ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY REGION, 2023–2030 (USD MILLION) 164
TABLE 139 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 164
TABLE 140 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES,
BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 141 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 142 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 143 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY REGION, 2023–2030 (USD MILLION) 166
TABLE 144 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 145 ANTIBODY DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 168
TABLE 146 ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 169
TABLE 147 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023–2030 (USD MILLION) 169
TABLE 148 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 149 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 150 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 171
TABLE 151 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 171
TABLE 152 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 171
TABLE 153 ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 172
TABLE 154 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 173
TABLE 155 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 173
TABLE 156 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 174
TABLE 157 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 174
TABLE 158 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 175
TABLE 159 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 175
TABLE 160 ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 176
TABLE 161 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER
END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 176
TABLE 162 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END USERS,
BY COUNTRY, 2023–2030 (USD MILLION) 177
TABLE 163 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 177
TABLE 164 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER
END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 178
TABLE 165 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 178
TABLE 166 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER
END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 178
TABLE 167 ANTIBODY DISCOVERY SERVICES MARKET, BY REGION,
2023–2030 (USD MILLION) 180
TABLE 168 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 182
TABLE 169 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 182
TABLE 170 NORTH AMERICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 183
TABLE 171 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET,
BY HOST, 2023–2030 (USD MILLION) 183
TABLE 172 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 184
TABLE 173 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 184
TABLE 174 NORTH AMERICA: KEY MACROINDICATORS 185
TABLE 175 US: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 186
TABLE 176 US: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 186
TABLE 177 US: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST,
2023–2030 (USD MILLION) 187
TABLE 178 US: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 187
TABLE 179 US: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 188
TABLE 180 CANADA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 189
TABLE 181 CANADA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 189
TABLE 182 CANADA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 190
TABLE 183 CANADA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 190
TABLE 184 CANADA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 191
TABLE 185 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 191
TABLE 186 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 192
TABLE 187 EUROPE: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 192
TABLE 188 EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 193
TABLE 189 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 193
TABLE 190 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 194
TABLE 191 EUROPE: KEY MACROINDICATORS 195
TABLE 192 GERMANY: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 196
TABLE 193 GERMANY: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 196
TABLE 194 GERMANY: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 197
TABLE 195 GERMANY: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 197
TABLE 196 GERMANY: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 198
TABLE 197 UK: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 199
TABLE 198 UK: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 199
TABLE 199 UK: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST,
2023–2030 (USD MILLION) 200
TABLE 200 UK: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 200
TABLE 201 UK: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 201
TABLE 202 FRANCE: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 202
TABLE 203 FRANCE: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 202
TABLE 204 FRANCE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 203
TABLE 205 FRANCE: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 203
TABLE 206 FRANCE: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 204
TABLE 207 ITALY: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 205
TABLE 208 ITALY: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 205
TABLE 209 ITALY: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 206
TABLE 210 ITALY: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 206
TABLE 211 ITALY: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 207
TABLE 212 SPAIN: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 208
TABLE 213 SPAIN: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 208
TABLE 214 SPAIN: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 209
TABLE 215 SPAIN: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 209
TABLE 216 SPAIN: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 210
TABLE 217 REST OF EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 210
TABLE 218 REST OF EUROPE: ANTIBODY ENGINEERING & OPTIMIZATION MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 211
TABLE 219 REST OF EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET,
BY HOST, 2023–2030 (USD MILLION) 211
TABLE 220 REST OF EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 212
TABLE 221 REST OF EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 212
TABLE 222 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 214
TABLE 223 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 214
TABLE 224 ASIA PACIFIC: ANTIBODY ENGINEERING & OPTIMIZATION MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 215
TABLE 225 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET,
BY HOST, 2023–2030 (USD MILLION) 215
TABLE 226 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 216
TABLE 227 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 216
TABLE 228 ASIA PACIFIC: KEY MACROINDICATORS 217
TABLE 229 CHINA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 218
TABLE 230 CHINA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 218
TABLE 231 CHINA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 219
TABLE 232 CHINA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 219
TABLE 233 CHINA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 220
TABLE 234 JAPAN: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 221
TABLE 235 JAPAN: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 221
TABLE 236 JAPAN: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 222
TABLE 237 JAPAN: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 222
TABLE 238 JAPAN: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 223
TABLE 239 INDIA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 224
TABLE 240 INDIA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 224
TABLE 241 INDIA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 225
TABLE 242 INDIA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 225
TABLE 243 INDIA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 226
TABLE 244 SOUTH KOREA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 227
TABLE 245 SOUTH KOREA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 227
TABLE 246 SOUTH KOREA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET,
BY HOST, 2023–2030 (USD MILLION) 228
TABLE 247 SOUTH KOREA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 228
TABLE 248 SOUTH KOREA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 229
TABLE 249 AUSTRALIA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 230
TABLE 250 AUSTRALIA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 230
TABLE 251 AUSTRALIA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 231
TABLE 252 AUSTRALIA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 231
TABLE 253 AUSTRALIA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 232
TABLE 254 REST OF ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 233
TABLE 255 REST OF ASIA PACIFIC: ANTIBODY ENGINEERING & OPTIMIZATION MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 233
TABLE 256 REST OF ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 234
TABLE 257 REST OF ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 234
TABLE 258 REST OF ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 235
TABLE 259 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 235
TABLE 260 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 236
TABLE 261 LATIN AMERICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 236
TABLE 262 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET,
BY HOST, 2023–2030 (USD MILLION) 237
TABLE 263 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 237
TABLE 264 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 238
TABLE 265 LATIN AMERICA: KEY MACROINDICATORS 238
TABLE 266 BRAZIL: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 239
TABLE 267 BRAZIL: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 240
TABLE 268 BRAZIL: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 240
TABLE 269 BRAZIL: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 241
TABLE 270 BRAZIL: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 241
TABLE 271 MEXICO: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 242
TABLE 272 MEXICO: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 242
TABLE 273 MEXICO: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 243
TABLE 274 MEXICO: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 243
TABLE 275 MEXICO: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 244
TABLE 276 REST OF LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 245
TABLE 277 REST OF LATIN AMERICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 245
TABLE 278 REST OF LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 246
TABLE 279 REST OF LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET,
BY MOLECULE, 2023–2030 (USD MILLION) 246
TABLE 280 REST OF LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 247
TABLE 281 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY REGION,
2023–2030 (USD MILLION) 247
TABLE 282 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 248
TABLE 283 MIDDLE EAST: ANTIBODY ENGINEERING & OPTIMIZATION MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 248
TABLE 284 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET,
BY HOST, 2023–2030 (USD MILLION) 249
TABLE 285 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 249
TABLE 286 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 250
TABLE 287 MIDDLE EAST: KEY MACROINDICATORS 250
TABLE 288 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 251
TABLE 289 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 251
TABLE 290 GCC COUNTRIES: ANTIBODY ENGINEERING & OPTIMIZATION MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 252
TABLE 291 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET,
BY HOST, 2023–2030 (USD MILLION) 252
TABLE 292 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 253
TABLE 293 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 253
TABLE 294 UAE: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 254
TABLE 295 UAE: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 254
TABLE 296 UAE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST,
2023–2030 (USD MILLION) 255
TABLE 297 UAE: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 255
TABLE 298 UAE: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 256
TABLE 299 KINGDOM OF SAUDI ARABIA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 257
TABLE 300 KINGDOM OF SAUDI ARABIA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 257
TABLE 301 KINGDOM OF SAUDI ARABIA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 258
TABLE 302 KINGDOM OF SAUDI ARABIA: ANTIBODY DISCOVERY SERVICES MARKET,
BY MOLECULE, 2023–2030 (USD MILLION) 258
TABLE 303 KINGDOM OF SAUDI ARABIA: ANTIBODY DISCOVERY SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 259
TABLE 304 REST OF GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 260
TABLE 305 REST OF GCC COUNTRIES: ANTIBODY ENGINEERING & OPTIMIZATION MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 260
TABLE 306 REST OF GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 261
TABLE 307 REST OF GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET,
BY MOLECULE, 2023–2030 (USD MILLION) 261
TABLE 308 REST OF GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 262
TABLE 309 REST OF MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 263
TABLE 310 REST OF MIDDLE EAST: ANTIBODY ENGINEERING & OPTIMIZATION MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 263
TABLE 311 REST OF MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 264
TABLE 312 REST OF MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 264
TABLE 313 REST OF MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 265
TABLE 314 AFRICA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 266
TABLE 315 AFRICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 266
TABLE 316 AFRICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 267
TABLE 317 AFRICA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 267
TABLE 318 AFRICA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 268
TABLE 319 AFRICA: KEY MACROINDICATORS 268
TABLE 320 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN ANTIBODY DISCOVERY SERVICES MARKET, JANUARY 2022–AUGUST 2025 269
TABLE 321 ANTIBODY DISCOVERY SERVICES MARKET: DEGREE OF COMPETITION 274
TABLE 322 ANTIBODY DISCOVERY SERVICES MARKET: REGION FOOTPRINT 278
TABLE 323 ANTIBODY DISCOVERY SERVICES MARKET: TYPE FOOTPRINT 279
TABLE 324 ANTIBODY DISCOVERY SERVICES MARKET: HOST FOOTPRINT 280
TABLE 325 ANTIBODY DISCOVERY SERVICES MARKET: MOLECULE FOOTPRINT 281
TABLE 326 ANTIBODY DISCOVERY SERVICES MARKET: LIST OF KEY STARTUPS/SME PLAYERS 284
TABLE 327 ANTIBODY DISCOVERY SERVICES MARKET: COMPETITIVE BENCHMARKING
OF KEY STARTUPS/SME PLAYERS, BY TYPE AND REGION 285
TABLE 328 ANTIBODY DISCOVERY SERVICES MARKET: SERVICE LAUNCHES,
JANUARY 2022–AUGUST 2025 288
TABLE 329 ANTIBODY DISCOVERY SERVICES MARKET: DEALS, JANUARY 2022–AUGUST 2025 288
TABLE 330 ANTIBODY DISCOVERY SERVICES MARKET: EXPANSIONS,
JANUARY 2022–AUGUST 2025 289
TABLE 331 WUXI BIOLOGICS: COMPANY OVERVIEW 291
TABLE 332 WUXI BIOLOGICS: SERVICES OFFERED 292
TABLE 333 WUXI BIOLOGICS: DEALS, JANUARY 2022–AUGUST 2025 293
TABLE 334 WUXI BIOLOGICS: EXPANSIONS, JANUARY 2022–AUGUST 2025 294
TABLE 335 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 295
TABLE 336 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED 296
TABLE 337 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–AUGUST 2025 297
TABLE 338 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–AUGUST 2025 298
TABLE 339 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW 300
TABLE 340 CHARLES RIVER LABORATORIES: SERVICES OFFERED 301
TABLE 341 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2022–AUGUST 2025 302
TABLE 342 EVOTEC: COMPANY OVERVIEW 304
TABLE 343 EVOTEC: SERVICES OFFERED 305
TABLE 344 EVOTEC: DEALS, JANUARY 2022–AUGUST 2025 306
TABLE 345 EVOTEC: CONTRACTS, JANUARY 2022–AUGUST 2025 307
TABLE 346 EVOTEC: EXPANSIONS, JANUARY 2022–AUGUST 2025 307
TABLE 347 EVOTEC: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 308
TABLE 348 BIOCYTOGEN: COMPANY OVERVIEW 309
TABLE 349 BIOCYTOGEN: SERVICES OFFERED 310
TABLE 350 BIOCYTOGEN: SERVICE LAUNCHES, JANUARY 2022−AUGUST 2025 311
TABLE 351 BIOCYTOGEN: DEALS, JANUARY 2022–AUGUST 2025 311
TABLE 352 BIOCYTOGEN: EXPANSIONS, JANUARY 2022–AUGUST 2025 313
TABLE 353 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 315
TABLE 354 EUROFINS SCIENTIFIC: SERVICES OFFERED 316
TABLE 355 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2022–AUGUST 2025 317
TABLE 356 SHANGHAI CHEMPARTNER: COMPANY OVERVIEW 318
TABLE 357 SHANGHAI CHEMPARTNER: SERVICES OFFERED 318
TABLE 358 SHANGHAI CHEMPARTNER: DEALS, JANUARY 2022–AUGUST 2025 319
TABLE 359 AURIGENE PHARMACEUTICAL SERVICES LTD. (DR. REDDY’S LABORATORIES): COMPANY OVERVIEW 320
TABLE 360 AURIGENE PHARMACEUTICAL SERVICES LTD. (DR. REDDY’S LABORATORIES): SERVICES OFFERED 322
TABLE 361 AURIGENE PHARMACEUTICAL SERVICES LTD. (DR. REDDY’S LABORATORIES): EXPANSIONS, JANUARY 2022–AUGUST 2025 323
TABLE 362 SINO BIOLOGICAL, INC.: COMPANY OVERVIEW 324
TABLE 363 SINO BIOLOGICAL, INC.: SERVICES OFFERED 325
TABLE 364 SINO BIOLOGICAL, INC.: DEALS, JANUARY 2022–AUGUST 2025 326
TABLE 365 SINO BIOLOGICAL, INC.: EXPANSIONS, JANUARY 2022–AUGUST 2025 327
TABLE 366 SAMSUNG BIOLOGICS: COMPANY OVERVIEW 328
TABLE 367 SAMSUNG BIOLOGICS: SERVICES OFFERED 329
TABLE 368 SAMSUNG BIOLOGICS: SERVICE LAUNCHES, JANUARY 2022–AUGUST 2025 330
TABLE 369 GENSCRIPT: COMPANY OVERVIEW 331
TABLE 370 GENSCRIPT: SERVICES OFFERED 332
TABLE 371 GENSCRIPT: SERVICE LAUNCHES, JANUARY 2022–AUGUST 2025 333
TABLE 372 GENSCRIPT: DEALS, JANUARY 2022–AUGUST 2025 334
TABLE 373 CURIA GLOBAL, INC.: COMPANY OVERVIEW 335
TABLE 374 CURIA GLOBAL, INC.: SERVICES OFFERED 335
TABLE 375 CURIA GLOBAL, INC.: DEALS, JANUARY 2022–AUGUST 2025 336
TABLE 376 CURIA GLOBAL, INC.: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 337
TABLE 377 TWIST BIOSCIENCE: COMPANY OVERVIEW 338
TABLE 378 TWIST BIOSCIENCE: SERVICES OFFERED 339
TABLE 379 TWIST BIOSCIENCE: SERVICE LAUNCHES, JANUARY 2022–AUGUST 2025 341
TABLE 380 TWIST BIOSCIENCE: DEALS, JANUARY 2022−AUGUST 2025 341
TABLE 381 TWIST BIOSCIENCE: EXPANSIONS, JANUARY 2022–AUGUST 2025 341
TABLE 382 HARBOUR BIOMED: COMPANY OVERVIEW 342
TABLE 383 HARBOUR BIOMED: SERVICES OFFERED 343
TABLE 384 HARBOUR BIOMED: DEALS, JANUARY 2022−AUGUST 2025 343
TABLE 385 HARBOUR BIOMED: OTHER DEVELOPMENTS, JANUARY 2022−AUGUST 2025 345
TABLE 386 ARAGEN LIFE SCIENCES LTD.: COMPANY OVERVIEW 346
TABLE 387 ARAGEN LIFE SCIENCES LTD.: SERVICES OFFERED 347
TABLE 388 ARAGEN LIFE SCIENCES LTD.: EXPANSIONS, JANUARY 2022–AUGUST 2025 347
TABLE 389 DANAHER CORPORATION: COMPANY OVERVIEW 348
TABLE 390 DANAHER CORPORATION: SERVICES OFFERED 349
TABLE 391 DANAHER CORPORATION: DEALS, JANUARY 2022–AUGUST 2025 350
TABLE 392 CREATIVE BIOLABS: COMPANY OVERVIEW 351
TABLE 393 CREATIVE BIOLABS: SERVICES OFFERED 351
TABLE 394 VIVA BIOTECH: COMPANY OVERVIEW 353
TABLE 395 VIVA BIOTECH: SERVICES OFFERED 355
TABLE 396 IMMUNOPRECISE ANTIBODIES LTD.: COMPANY OVERVIEW 356
TABLE 397 IMMUNOPRECISE ANTIBODIES LTD.: SERVICES OFFERED 357
TABLE 398 IMMUNOPRECISE ANTIBODIES LTD.: DEALS, JANUARY 2022−AUGUST 2025 359
TABLE 399 FUSION ANTIBODIES: COMPANY OVERVIEW 360
TABLE 400 FUSION ANTIBODIES: SERVICES OFFERED 361
TABLE 401 ABZENA: COMPANY OVERVIEW 363
TABLE 402 ALLOY THERAPEUTICS, INC.: COMPANY OVERVIEW 364
TABLE 403 INTEGRAL MOLECULAR: COMPANY OVERVIEW 365
TABLE 404 BIODURO: COMPANY OVERVIEW 366
TABLE 405 SYNBIO TECHNOLOGIES: COMPANY OVERVIEW 367
TABLE 406 ABSOLUTE ANTIBODY: COMPANY OVERVIEW 368
TABLE 407 ADIMAB: COMPANY OVERVIEW 369
TABLE 408 ISOGENICA: COMPANY OVERVIEW 370
TABLE 409 ABLEXIS: COMPANY OVERVIEW 371
TABLE 410 FAIRJOURNEY: COMPANY OVERVIEW 372
LIST OF FIGURES
FIGURE 1 ANTIBODY DISCOVERY SERVICES MARKET SEGMENTATION & REGIONAL SCOPE 36
FIGURE 2 ANTIBODY DISCOVERY SERVICES MARKET: YEARS CONSIDERED 37
FIGURE 3 ANTIBODY DISCOVERY SERVICES MARKET: RESEARCH DESIGN 39
FIGURE 4 ANTIBODY DISCOVERY SERVICES MARKET: BREAKDOWN OF PRIMARIES
(SUPPLY- AND DEMAND-SIDE PARTICIPANTS) 41
FIGURE 5 ANTIBODY DISCOVERY SERVICES MARKET SIZE ESTIMATION
(SUPPLY-SIDE ANALYSIS), 2024 42
FIGURE 6 COMPANY REVENUE ANALYSIS-BASED MARKET SIZE ESTIMATION:
BOTTOM-UP APPROACH 43
FIGURE 7 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC (US), 2024 44
FIGURE 8 ANTIBODY DISCOVERY SERVICES MARKET SIZE VALIDATION
FROM PRIMARY EXPERTS 45
FIGURE 9 ANTIBODY DISCOVERY SERVICES MARKET SIZE ESTIMATION METHODOLOGY:
TOP-DOWN APPROACH 45
FIGURE 10 ANTIBODY DISCOVERY SERVICES MARKET: CAGR PROJECTIONS 47
FIGURE 11 ANTIBODY DISCOVERY SERVICES MARKET: DATA TRIANGULATION METHODOLOGY 49
FIGURE 12 ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,
2025 VS. 2030 (USD MILLION) 53
FIGURE 13 ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY,
2025 VS. 2030 (USD MILLION) 53
FIGURE 14 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST,
2025 VS. 2030 (USD MILLION) 54
FIGURE 15 ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE,
2025 VS. 2030 (USD MILLION) 55
FIGURE 16 ANTIBODY DISCOVERY SERVICES MARKET, BY END USER,
2025 VS. 2030 (USD MILLION) 55
FIGURE 17 ANTIBODY DISCOVERY SERVICES MARKET: REGIONAL SNAPSHOT 56
FIGURE 18 SNAPSHOT: GLOBAL ANTIBODY DISCOVERY SERVICES MARKET SIZE,
GROWTH RATE, AND FORECAST (USD MILLION) 60
FIGURE 19 INCREASING VENTURE FUNDING AND INVESTMENTS TO DRIVE MARKET 61
FIGURE 20 US AND MONOCLONAL ANTIBODIES COMMANDED LARGEST NORTH AMERICAN MARKET SHARE IN 2024 62
FIGURE 21 MONOCLONAL ANTIBODIES TO ACCOUNT FOR LARGEST MARKET SHARE THROUGHOUT FORECAST PERIOD 63
FIGURE 22 CHINA TO REGISTER HIGHEST CAGR FROM 2025 TO 2030 63
FIGURE 23 ANTIBODY ENGINEERING & OPTIMIZATION SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2024 64
FIGURE 24 ANTIBODY DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 71
FIGURE 25 ANTIBODY DISCOVERY SERVICES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 77
FIGURE 26 ANTIBODY DISCOVERY SERVICES MARKET: VALUE CHAIN ANALYSIS 78
FIGURE 27 ANTIBODY DISCOVERY SERVICES MARKET: ECOSYSTEM ANALYSIS 79
FIGURE 28 NIH FUNDING FOR ANTIBODY DISCOVERY, 2014–2025 (USD MILLION) 83
FIGURE 29 TOP PATENT APPLICANTS/OWNERS AND NUMBER OF PATENTS GRANTED IN ANTIBODY DISCOVERY SERVICES MARKET, JANUARY 2014–DECEMBER 2024 87
FIGURE 30 ANTIBODY DISCOVERY SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 95
FIGURE 31 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY TYPE 97
FIGURE 32 KEY BUYING CRITERIA FOR MAJOR END USERS 98
FIGURE 33 IMPACT OF AI/GEN AI ON ANTIBODY DISCOVERY SERVICES MARKET 100
FIGURE 34 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET SNAPSHOT 181
FIGURE 35 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET SNAPSHOT 213
FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS IN ANTIBODY DISCOVERY SERVICES MARKET, 2020–2024 (USD MILLION) 272
FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ANTIBODY DISCOVERY
SERVICES MARKET (2024) 274
FIGURE 38 ANTIBODY DISCOVERY SERVICES MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2024 276
FIGURE 39 ANTIBODY DISCOVERY SERVICES MARKET: COMPANY FOOTPRINT 277
FIGURE 40 ANTIBODY DISCOVERY SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 283
FIGURE 41 EV/EBITDA OF KEY PLAYERS 286
FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA
OF KEY PLAYERS 286
FIGURE 43 ANTIBODY DISCOVERY SERVICES MARKET: BRAND/SERVICE
COMPARATIVE ANALYSIS 287
FIGURE 44 WUXI BIOLOGICS: COMPANY SNAPSHOT 292
FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 296
FIGURE 46 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT 301
FIGURE 47 EVOTEC: COMPANY SNAPSHOT 305
FIGURE 48 BIOCYTOGEN: COMPANY SNAPSHOT 310
FIGURE 49 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT 316
FIGURE 50 AURIGENE PHARMACEUTICAL SERVICES LTD. (DR. REDDY’S LABORATORIES): COMPANY SNAPSHOT 321
FIGURE 51 SINO BIOLOGICAL, INC.: COMPANY SNAPSHOT 325
FIGURE 52 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT 329
FIGURE 53 GENSCRIPT: COMPANY SNAPSHOT 332
FIGURE 54 TWIST BIOSCIENCE: COMPANY SNAPSHOT 339
FIGURE 55 HARBOUR BIOMED: COMPANY SNAPSHOT 342
FIGURE 56 ARAGEN LIFE SCIENCES LTD.: COMPANY SNAPSHOT 346
FIGURE 57 DANAHER CORPORATION: COMPANY SNAPSHOT 349
FIGURE 58 VIVA BIOTECH: COMPANY SNAPSHOT 354
FIGURE 59 IMMUNOPRECISE ANTIBODIES LTD.: COMPANY SNAPSHOT 357
FIGURE 60 FUSION ANTIBODIES: COMPANY SNAPSHOT 361
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11